000 01558cam  2200361zi 4500
0019.937285
003CaOODSP
00520240620103038
006m     o  d f      
007cr |||||||||||
008240422e202405  onc     o    f000 0 eng d
020 |a9780660715179
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH164-362/2024E-PDF
24500|aGuidance on submitting pediatric development plans and pediatric studies.
264 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cMay 2024.
264 4|c©2024
300 |a1 online resource (32 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Lignes directrices sur la présentation de plans de développement pédiatrique et d'études pédiatriques.
500 |a"Effective date: 2024-02-26."
500 |a"Pub.: 240083."
650 0|aPediatrics|zCanada.
650 0|aDrug approval|zCanada.
650 0|aPharmaceutical policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLignes directrices sur la présentation de plans de développement pédiatrique et d'études pédiatriques.|w(CaOODSP)9.937286
85640|qPDF|s696 KB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H164-362-2024-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/pediatrics/guidance-submitting-development-plans-studies.html